You already watch estradiol and hematocrit like a hawk. But there's a lipid signal that quietly changes on testosterone therapy — one that a system-by-system optimizer should have on the dashboard from day one, not discover a year later.
The biomarker you may be underweighting
Most men starting testosterone replacement therapy (TRT) build their monitoring plan around three things: total and free testosterone, estradiol, and hematocrit. That's appropriate — the Endocrine Society's clinical practice guideline explicitly calls for baseline and follow-up testosterone, hematocrit, and prostate assessment [1]. But lipids sit in the same conversation, and HDL cholesterol in particular can move in a direction that surprises the uninitiated.
Exogenous testosterone — especially at higher exposures or with certain formulations — has been associated in the literature with reductions in HDL cholesterol [2][3]. This is not a reason to avoid therapy; it's a reason to measure. For someone who tracks recovery, VO2 signals, and hormone ratios with precision, a lipid panel is simply another instrument on the same console.
Why testosterone can nudge HDL down
The mechanism is not fully settled, but the leading explanation involves hepatic lipase. Androgens can increase the activity of this liver enzyme, which accelerates the breakdown of HDL particles [2]. The effect appears more pronounced with supraphysiologic exposure and with oral or high-dose androgens than with careful, physiologic replacement — which is one more argument for a protocol that keeps you inside a sensible range rather than chasing a number.
What matters for you as an optimizer is that HDL is only one line in a larger picture. LDL cholesterol, non-HDL cholesterol, triglycerides, and — increasingly — apolipoprotein B (ApoB), which counts the actual number of atherogenic particles, together tell a more complete story than any single value [4][5]. A modest HDL shift in isolation means less than the trajectory of your full lipid and cardiovascular risk profile over time.
What the cardiovascular data actually says
The long-standing question — does TRT raise cardiovascular risk? — was examined in the TRAVERSE trial, a large randomized study in middle-aged and older men with hypogonadism and existing or high cardiovascular risk. Published in the New England Journal of Medicine, it reported that testosterone was noninferior to placebo for major adverse cardiac events over the study period, while noting higher rates of certain events such as atrial fibrillation and pulmonary embolism [6].
That nuance is the whole point: the headline is reassuring on the primary endpoint, but the details are exactly what a responsive provider watches. A lipid shift is one input into an ongoing risk conversation, not a verdict on your protocol.
Source: [6] Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE), NEJM
The metrics a provider tracks from the start
A thorough independent provider treating a high performer typically establishes a baseline before therapy and re-checks on a defined cadence. The categories usually include:
- Androgens and estrogen: total and free testosterone, plus estradiol, since aromatization is part of the picture you already care about [1].
- Hematocrit: because testosterone can raise red blood cell mass, guidelines call for monitoring and thresholds for action [1].
- Lipids: a full panel — HDL, LDL, non-HDL, triglycerides — and, where a provider deems it useful, ApoB and lipoprotein(a) for a sharper view of atherogenic burden [4][5].
- Prostate-specific antigen (PSA) and symptoms: per age-appropriate screening within the guideline framework [1].
The goal isn't more labs for their own sake. It's a baseline you can trend against, so that if HDL moves, your provider can see whether your overall cardiovascular risk picture is holding or drifting — and adjust accordingly, rather than reacting to a single out-of-context value.
Source: [1] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
What to do if HDL drifts
This is where responsiveness beats a once-a-year check-in. An HDL change on TRT is a prompt for a conversation about the whole system, not an automatic reason to stop. Depending on the full picture, an independent provider might revisit training and nutrition patterns, evaluate whether formulation or exposure is contributing, look harder at LDL and ApoB, and weigh your global cardiovascular risk before making any change.
Because you're already the kind of person who reads the primary literature, you'll appreciate the framing: lipids are dynamic, they respond to many inputs beyond hormones, and the meaningful question is always the direction of your ApoB-anchored risk over quarters and years — not one lonely HDL reading in isolation.
This article is educational and is not medical advice. Whether any therapy is appropriate for you — and what monitoring it requires — is a decision only a licensed provider can make after evaluating your history, labs, and goals.
Where Velri fits
Velri is a technology and coordination company; it does not provide medical care. What Velri can do is remove the friction that made past concierge care feel shallow and slow. Velri coordinates lab work so your baseline and follow-up panels — androgens, estradiol, hematocrit, and lipids — are organized in one place, then connects you with an independent, licensed provider who can review that data and engage at the level of detail you expect. If, and only if, that independent provider determines therapy is appropriate, any prescription is fulfilled through an independent licensed pharmacy. A prescription is never guaranteed and is always the provider's clinical decision.
Where a provider discusses compounded options: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
